NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
68
Frequently Asked Questions
What is Market Cap of NewAmsterdam Pharma Company NV?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. NewAmsterdam Pharma Company NV market cap is $2.72B.
What is the 52-week high for NewAmsterdam Pharma Company NV?
52 week high is the highest price of a stock in the past 52 weeks, or one year. NewAmsterdam Pharma Company NV 52 week high is $27.35 as of September 16, 2025.
What is the 52-week low for NewAmsterdam Pharma Company NV?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. NewAmsterdam Pharma Company NV 52 week low is $14.06 as of September 16, 2025.
What is NewAmsterdam Pharma Company NV stock price today?
NewAmsterdam Pharma Company NV stock price today is $24.52.
What was NewAmsterdam Pharma Company NV stock price yesterday?
NewAmsterdam Pharma Company NV stock price yesterday was $24.12.
What is the PE ratio of NewAmsterdam Pharma Company NV?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. NewAmsterdam Pharma Company NV’s P/E ratio is -14.96.
What is the Price-to-Book ratio of NewAmsterdam Pharma Company NV?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. NewAmsterdam Pharma Company NV P/B ratio is 3.4859.
What is the 50-day moving average of NewAmsterdam Pharma Company NV?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. NewAmsterdam Pharma Company NV 50-day moving average is $23.67.
How many employess does NewAmsterdam Pharma Company NV has?
